To reduce the hepatotoxicity observed with systemic CD137 agonism with urelumab while maintaining potency, restricting CD137+ T cell agonism to the tumor microenvironment by targeting CD137 with bispecific format molecules that simultaneously engage tumor associated antigens (TAA) appear to be an ideal approach. This evidence concerns the gene TNFRSF9 and neoplasm.